Cosentyx (secukinumab) is a medication used to treat certain autoimmune diseases such as psoriasis and psoriatic arthritis. There is limited information available regarding the safety of Cosentyx in breastfeeding mothers. According to Drugs.com [3], it is unknown whether secukinumab is excreted in human milk, and the manufacturer recommends that women should not breastfeed while taking Cosentyx.

The National Library of Medicine [2] states that it is unclear whether secukinumab is excreted in human milk and the potential risks to a nursing infant are unknown. Therefore, a decision should be made whether to discontinue nursing or to discontinue the medication, taking into account the importance of the drug to the mother.

Additionally, according to Drug Patent Watch [1], the safety and effectiveness of Cosentyx in children and infants have not been established. Therefore, it is recommended that women who are breastfeeding should consult with their healthcare provider before taking Cosentyx.

In conclusion, the safety of Cosentyx in breastfeeding mothers is unclear, and there is limited information available. Women who are breastfeeding and considering taking Cosentyx should consult with their healthcare provider to determine the potential risks and benefits of the medication for themselves and their infants.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.ncbi.nlm.nih.gov/books/NBK500738/
[3] https://www.drugs.com/breastfeeding/secukinumab.html